



University of Groningen

In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation

Blasi, Annabel; von Meijenfeldt, Fien A.; Adelmeijer, Jelle; Calvo, Andrea; Ibanez, Cristina; Perdomo, Juan; Reverter, Juan C.; Lisman, Ton

Published in:
JOURNAL OF THROMBOSIS AND HAEMOSTASIS

DOI:
[10.1111/jth.15043](https://doi.org/10.1111/jth.15043)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Blasi, A., von Meijenfeldt, F. A., Adelmeijer, J., Calvo, A., Ibanez, C., Perdomo, J., Reverter, J. C., & Lisman, T. (2020). In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. *JOURNAL OF THROMBOSIS AND HAEMOSTASIS*, 18(10), 2646-2653. <https://doi.org/10.1111/jth.15043>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

BRIEF REPORT

In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation

Annabel Blasi¹ | Fien A. von Meijenfildt² | Jelle Adelmeijer² | Andrea Calvo¹ | Cristina Ibañez¹ | Juan Perdomo¹ | Juan C. Reverter³ | Ton Lisman² 

¹Anesthesiology Department, Hospital Clínic, Institute d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

²Surgical Research Laboratory, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

³Department of Hemostasis, Hospital Clínic, Agustí Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain

Correspondence

Ton Lisman, Department of Surgery, University Medical Center Groningen, BA33, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.

Email: j.a.lisman@umcg.nl

Abstract

Background: COVID-19 is associated with a substantial risk of venous thrombotic events, even in the presence of adequate thromboprophylactic therapy.

Objectives: We aimed to better characterize the hypercoagulable state of COVID-19 patients in patients receiving anticoagulant therapy.

Methods: We took plasma samples of 23 patients with COVID-19 who were on prophylactic or intensified anticoagulant therapy. Twenty healthy volunteers were included to establish reference ranges.

Results: COVID-19 patients had a mildly prolonged prothrombin time, high von Willebrand factor levels and low ADAMTS13 activity. Most rotational thromboelastometry parameters were normal, with a hypercoagulable maximum clot firmness in part of the patients. Despite detectable anti-activated factor X activity in the majority of patients, ex vivo thrombin generation was normal, and in vivo thrombin generation elevated as evidenced by elevated levels of thrombin-antithrombin complexes and D-dimers. Plasma levels of activated factor VII were lower in patients, and levels of the platelet activation marker soluble CD40 ligand were similar in patients and controls. Plasmin-antiplasmin complex levels were also increased in patients despite an in vitro hypofibrinolytic profile.

Conclusions: COVID-19 patients are characterized by normal in vitro thrombin generation and enhanced clot formation and decreased fibrinolytic potential despite the presence of heparin in the sample. Anticoagulated COVID-19 patients have persistent in vivo activation of coagulation and fibrinolysis, but no evidence of excessive platelet activation. Ongoing activation of coagulation despite normal to intensified anticoagulant therapy indicates studies on alternative antithrombotic strategies are urgently required.

Manuscript handled by: Katsue Suzuki-Inoue

Final decision: Katsue Suzuki-Inoue, 3 August 2020

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2020 The Authors. *Journal of Thrombosis and Haemostasis* published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis

KEYWORDS

anticoagulation, coagulation, COVID-19, fibrinolysis

1 | INTRODUCTION

Patients with COVID-19 have a profound risk for venous thrombotic events. Particularly in patients admitted to an intensive care unit (ICU), rates of deep vein thrombosis and pulmonary embolism are exceedingly high, even in the presence of pharmacological thromboprophylaxis.^{1,2} In addition to macrovascular thrombotic events, microvascular thrombosis has been proposed to contribute to disease progression, with pulmonary clots contributing to respiratory failure,³⁻⁵ and clots in other vascular beds to multiple organ failure.^{6,7} Anticoagulant treatment has been shown to reduce mortality, perhaps because of reduction of microvascular thromboses.⁸

The high thrombosis risk in COVID-19 patients has been linked to a hypercoagulable state that has not been well defined. The *in vivo* hyperactivation of coagulation appears to be linked to a massive inflammatory response coupled with increases in acute phase proteins including fibrinogen,⁹ and involvement of neutrophil extracellular traps (NETs),¹⁰ which are newly recognized actors in thrombosis. Routine hemostasis tests show mild prolongations in prothrombin time and activated partial thromboplastin time, and mild thrombocytopenia in some patients, but massively elevated levels of D-dimer in many patients,⁹ that appear to have prognostic value.¹¹ Whole blood thromboelastography has demonstrated a hypercoagulable profile,^{12,13} and one of these studies concluded that the COVID-19 coagulopathy does not have elements of typical disseminated intravascular coagulation, as has been suggested by others.¹³ Notably, increased (major) bleeding complications have been described in COVID-19 patients, especially in the critically ill, suggesting a fragile balance in hemostatic status of these patients,¹⁴ although others have demonstrated bleeding risks comparable to patients with non-COVID-19 acute respiratory syndromes.

In a large academic medical center in Barcelona, Spain, to which approximately 600 patients were admitted at the peak of the COVID-19 pandemic, the initial reports on thrombosis and hypercoagulability and their own observations led to an intensified thromboprophylactic regimen for part of the admitted COVID-19 patients, particularly those with more advanced disease. Although an anticoagulant protocol was instituted, during the period of our study, this protocol was poorly adhered to and individualized decisions on anticoagulant dosing were taken. We aimed to study the effects of this individualized anticoagulant therapy on the hemostatic status of these patients.

2 | MATERIALS AND METHODS

2.1 | Patients

We included 23 patients that were admitted with COVID-19 (which was confirmed by PCR) to Hospital Clínic Barcelona, Spain, in April

Essentials

- COVID-19 patients are at increased risk for venous thrombotic events, despite thromboprophylaxis.
- Hemostatic status of 23 COVID-19 patients on anticoagulant therapy was studied in plasma.
- *In vitro*: normal coagulation, enhanced clot formation and hypofibrinolysis despite heparin.
- Persistent *in vivo* activation of coagulation and fibrinolysis despite anticoagulant therapy.

2020. Almost all patients received the low molecular weight heparin (LMWH) enoxaparin. Ethical approval from the Medical Ethical Committee Hospital Clínic Barcelona (2020/0371) was obtained. All patients, or in the case of incapacity their consultee, gave informed consent or assent, respectively, for participation in this study. Twenty healthy controls were included to establish reference values for the various assays performed. Exclusion criteria for healthy controls were age younger 18 years, pregnancy, hereditary thrombophilia or hemophilia, use of anticoagulant medications, history of venous thromboembolic events, and blood (product) transfusion up to 7 days before inclusion.

2.2 | Sampling

Citrated blood samples were taken 4 (2-6) days after admission to the hospital (9 [6-13] days after onset of symptoms) on either a general ward or ICU by venipuncture or from dedicated arterial lines. In all patients, anticoagulation was started on admission. Blood samples were either used immediately for rotational thromboelastometry (ROTEM) measurements or processed to platelet-poor plasma within 30 minutes of the blood draw by double centrifugation at 2500g for 15 minutes, and subsequently stored at -80°C until used for analyses. Complete blood cell counts, and creatinine, total bilirubin, and C-reactive protein were measured as part of routine clinical care by the Centre de Diagnòstic Biomèdic at the Hospital Clínic Barcelona.

2.3 | Assays

We measured PT, activated partial thromboplastin time, international normalized ratio, prothrombin, antithrombin, fibrinogen, and D-dimer on an automated coagulation analyzer (STACompact 3, Stago) using reagents and protocols from the manufacturer. Von Willebrand factor (VWF) plasma levels were determined with an in-house ELISA using commercially available polyclonal antibodies against VWF (DAKO). Plasma

activity of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) was measured using the FRET-S-VWF73 assay (Peptanova). Levels of VWF and ADAMTS13 in pooled normal plasma were set at 100%, and values obtained in test plasmas were expressed as a percentage of pooled normal plasma. Plasminogen activator inhibitor type 1 levels were quantified by commercially available ELISA from R&D Systems. Cell-free DNA was quantified using the Quant-iT PicoGreen dsDNA assay kit (Fisher Scientific), as described previously.¹⁶ The concentration of myeloperoxidase DNA complexes in plasma was determined by ELISA, as previously described.¹⁷

ROTEM analyses were performed on a ROTEM sigma according to the manufacturers' instructions. Thrombin generation was performed as previously described¹⁸ using commercially available reagents containing recombinant tissue factor (final concentration: 5 pmol/L), phospholipids (final concentration: 4 μ mol/L), and soluble thrombomodulin (the concentration of which is not revealed by the manufacturer) (Thromboscope BV). Anti-activated factor X (anti-Xa) levels were measured on an automated analyzer (ACL 300 TOP) using Heparin LRT (Hyphen Biomed).

Plasma fibrinolytic potential was estimated by studying lysis of a tissue factor-induced clot by exogenous tissue plasminogen activator by monitoring changes in turbidity during clot formation and subsequent lysis, as described previously.¹⁹ Samples that were still clotted at 3 hours after the start of the experiment were arbitrarily assigned a clot lysis time (CLT) of 180 minutes.

Plasma levels of thrombin-antithrombin (TAT) complexes, prothrombin fragment 1 + 2 (F1 + 2), plasmin-antiplasmin (PAP) complexes, and soluble CD40 ligand were quantified by commercially available ELISAs (Siemens, for TAT and F1 + 2, Technoclone, for PAP, and R&D Systems, Bio-technie, for sCD40L). Plasma levels of activated factor VII were quantified using the Hemoclot factor VIIa kit (Hyphen Biomed).

2.4 | Statistical analyses

Statistical analyses were performed using GraphPad Prism, version 8.3.1 (San Diego, CA). The results were presented as numbers (percentages) for categorical variables and medians [interquartile ranges] for continuous variables. Test results were compared between COVID-19 patients and healthy controls, and between patients admitted to the ICU and the ward, using the Mann-Whitney *U* test. Relations between laboratory parameters were made by simple linear regression. *P* values < .05 were considered statistically significant.

3 | RESULTS AND DISCUSSION

3.1 | Abnormalities in diagnostic hemostasis tests in COVID-19 patients

We studied 23 patients of whom 12 were admitted to the ICU, with 11 on general wards. None of the ward patients later had to be

admitted to the ICU. Three ICU patients developed thrombotic complications: one pulmonary embolism, one myocardial infarction, and one distal ischemia of the fingers. General patient characteristics are shown in Table 1. Most ICU patients received higher anticoagulant doses compared with ward patients; Table 1). Routine diagnostic hemostasis tests and plasma levels of markers for NETs are shown in Table 2. Compared with healthy controls, patients had a prolonged prothrombin time and international normalized ratio, which are largely explained by decreased FVII levels that strongly correlated with the prothrombin time ($r^2 = .56$, $P < .0001$). In addition, patients had a decreased platelet count, elevated fibrinogen levels, slightly decreased levels of prothrombin and antithrombin, high levels of VWF and FVIII, and low levels of ADAMTS13. Of note, four patients had prothrombin and antithrombin levels < 25%, and two other patients had ADAMTS13 levels < 10%. These results are consistent with a mild consumption coagulopathy with a thrombogenic VWF profile. Plasma levels of plasminogen activator inhibitor type 1 were approximately 3.7 times higher in COVID-19 patients compared with controls. Markers of NETs were modestly elevated in patients compared with controls, and did not differ between patients that were or were not admitted to ICU, which may argue against a key role of NETs in the pathogenesis of COVID-19 associated sequelae, as was suggested previously. Indeed, unlike previously described,¹⁰ NET markers in our cohort did not correlate with C-reactive protein, D-dimer, platelet count, or use of mechanical ventilation.

3.2 | Normal to hypercoagulable ex vivo clot formation, thrombin generation, and mild hypofibrinolysis

We next studied hemostatic potential of COVID-19 patients by three global tests (Table 3). ROTEM parameters were largely within the normal range, except for elevated maximum clot firmness in extem, intem, and fibtem in 6, 8, and 11 patients, respectively. A limitation of these analyses was that normal ranges were not locally established, but taken from the ROTEM user manual. Of note, ROTEM extem and fibtem reagents contain polybrene, which neutralizes heparin present in many of these samples. Thrombomodulin-modified thrombin generation was preserved on a group level, but individual patients were clearly hyper- or hypocoagulable. The patient samples that generated little thrombin contained high levels of LMWH as evidenced by anti-Xa activity assays, whereas hypercoagulable samples generally had low to undetectable anti-Xa activity, although one patient had marked thrombin generation even in the presence of high anti-Xa levels. ETP and peak thrombin levels were inversely correlated with anti-Xa levels ($r^2 = .16$, $P = .055$ and $r^2 = .20$, $P = .03$; without one clear outlier, these correlations became much stronger $r^2 = .54$, $P < .0001$ and $r^2 = .50$, $P = .0002$). Samples taken from patients admitted to the ICU generated substantially less thrombin, but this was directly related to much higher anti-Xa levels in samples taken from patients on the ICU compared with ward patients

TABLE 1 Patient characteristics

Variable	COVID-19 Patients (n = 23)	COVID-19 Patients ICU (n = 12)	COVID-19 Patients Ward (n = 11)	Healthy Controls (n = 20)	P Value Patients vs Controls	P Value ICU vs Ward
Age	64 [53-74]	69 [57-76]	58 [42-74]	44 [39-50]	<.001	.267
Female	9 (39%)	6 (50%)	3 (27%)	9 (45%)	.697	.265
Body mass index (kg/m ²)	30 [27-34]	32 [27-35]	29 [27-31]	24 [20-27]	<.0001	.285
SOFA score	3.0 [1.0-6.0]	5.5 [3.3-7.8]	2.0 [0.0-3.0]			.01
APACHE score	12.0 [5.0-16.0]	15.5 [12.0-17.8]	5.0 [3.0-10.0]			<.0001
Pulmonary support						
Intubated	12 (52%)	12 (100%)	0 (0%)			<.0001
Noninvasive ventilation	1 (4%)	0 (0%)	1 (9%)			.286
Nasal oxygen	10 (43%)	0 (0%)	10 (91%)			<.0001
PaO ₂ /FiO ₂ (PaFI)	367 [208-420]	239 [130-414]	418 [325-420]			.121
Respiratory rate (/min)	22 [18-28]	27 [26-32]	18 [18-20]			.0002
SIRS criteria (≥2)	8 (35%)	6 (50%)	2 (18%)			.110
DIC score (≥5)	2 (9%)	1 (8%)	1 (9%)			.949
Glasgow coma scale (≤8)	3 (13%)	2 (17%)	1 (9%)			.590
Underlying (chronic) disease						
Cardiovascular disease	13 (57%)	8 (67%)	5 (45%)			.305
Cirrhosis	5 (22%)	1 (8%)	4 (36%)			.104
Diabetes	4 (17%)	2 (17%)	2 (18%)			.924
Onset of symptoms before admission (days)	6 [5-8]	7 [5-10]	6 [5-7]			.626
Blood sampling day (since admission)	4 [2-6]	5 [4-7]	2 [1-2]			<.0001
Baseline laboratory values						
Creatinine (mg/dL)	0.80 [0.42-2.10]	0.63 [0.29-2.09]	0.80 [0.56-2.10]			.281
C-reactive protein (mg/L)	2.33 [0.70-5.57]	0.77 [0.42-2.59]	3.28 [2.33-8.96]			.009
Lactate (mg/dL)	15 [12-16]	15 [13-19]	15 [9-15]			.374
LDH (U/L)	307 [236-424]	345 [258-660]	305 [193-354]			.300
pH	7.41 [7.33-7.45]	7.45 [7.32-7.47]	7.38 [7.33-7.43]			.169
Total bilirubin (mg/ dL)	0.80 [0.40-1.30]	0.80 [0.45-1.23]	0.60 [0.40-1.30]			.682
WBC count (×10 ⁹ /L)	6.3 [3.4-11.8]	10.5 [6.7-15.3]	3.5 [3.1-4.5]	5.88 [5.26-7.93]	.995	.007
Anticoagulation (LMWH)						
No	2 (9%)	0 (0%)	2 (18%)			.122
<0.5 mg/kg/d	7 (30%)	2 (17%)	5 (45%) ^a			.134
0.5-1.5 mg/kg/d	9 (39%)	6 (50%)	3 (27%)			.265
≥1.5 mg/kg/d	5 (22%)	4 (33%) ^b	1 (9%)			.159

(Continues)

TABLE 1 (Continued)

Variable	COVID-19 Patients (n = 23)	COVID-19 Patients ICU (n = 12)	COVID-19 Patients Ward (n = 11)	Healthy Controls (n = 20)	P Value Patients vs Controls	P Value ICU vs Ward
Outcome						
Duration of hospital stay in days (n = 21)	25 [7.5-44]	43 [21-46]	11 [5.0-26]			.015
Still in hospital	2 (9%)	2 (17%)	0 (0%)			.157
Death	4 (17%)	2 (17%)	2 (18%)			.924

Note: The results are presented as median [interquartile range] for continuous variables, and number (percentage) for categorical variables. Comparisons between the two groups are made using the Mann-Whitney *U* test or chi-squared test, as appropriate.

Abbreviations: DIC, disseminated intravascular coagulation; ICU, intensive care unit; LDH, lactate dehydrogenase; LMWH, low-molecular-weight heparin; SIRS, systemic inflammatory response syndrome; SOFA, sequential organ failure assessment; WBC, white blood cell.

^aOne patient received tinzaparin sodium 3500 International Units per day.

^bOne ICU patient received intravenous infusion of unfractionated heparin.

TABLE 2 Various laboratory values in healthy controls and COVID patients with additional subdivision in ICU and non-ICU patients

	Controls (n = 20)	COVID-19 Patients (n = 23)	P Value	ICU (n = 12)	Non-ICU (n = 11)	P Value
Standard hemostasis tests						
PT (s)	10.9 [10.7-11.3]	15.9 [15.3-18.6]	<.0001	15.6 [15.2-16.4]	18.6 [15.8-19.8]	.046
APTT (s)	33.4 [31.4-35.0]	34.6 [31.2-39.7]	.113	33.7 [31.2-41.5]	36.0 [31.2-39.7]	.707
INR	1.01 [0.99-1.05]	1.15 [1.11-1.34]	<.0001	1.13 [1.10-1.19]	1.34 [1.15-1.42]	.049
Platelet count (10 ⁹ /L)	244 [184-323]	167 [136-250]	.039	196 [127-293]	167 [154-239]	.940
Additional hemostasis tests						
Fibrinogen (g/L)	3.00 [2.77-3.50]	4.51 [2.82-5.15]	.021	3.93 [3.00-4.88]	5.02 [1.72-5.52]	.413
Prothrombin (%)	130 [113-144]	85 [50-99]	<.0001	84 [64-96]	87 [48-100]	.893
Antithrombin (%)	113 [104-126]	102 [51-121]	.016	106 [76-126]	85 [43-115]	.206
VWF (%)	132 [95.5-176]	306 [200-421]	<.0001	367 [296-464]	216 [180-319]	.015
FVIII (%) ^a	88 [72-110]	161 [129-216]	<.0001	172 [136-235]	160 [96-195]	.234
FVII (%) ^a	90 [81-99]	71 [55-85]	.0034	76 [66-91]	60 [44-78]	.052
ADAMTS13 (%)	101 [83.3-116]	47.3 [25.8-66.1]	<.0001	46.2 [27.4-57.8]	59.9 [25.8-70.3]	.449
PAI-1 (ng/mL)	0.70 [0.33-1.45]	2.60 [2.00-3.08]	<.0001	2.35 [1.70-3.08]	2.60 [2.00-5.30]	.705
NET markers						
Cell-free DNA (μg/mL)	0.89 [0.87-0.96]	1.28 [1.15-1.45]	<.0001	1.33 [1.27-1.47]	1.22 [1.12-1.37]	.062
MPO-DNA complexes (AU)	0.07 [0.05-0.10]	0.14 [0.10-0.57]	<.001	0.13 [0.09-0.17]	0.18 [0.12-0.79]	.094

Note: The results are presented as median [interquartile range]. Comparisons between the two groups were made using the Mann-Whitney *U* test for nonparametric data.

Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; APTT, activated partial thromboplastin time; ICU, intensive care unit; INR, international normalized ratio; MPO, myeloperoxidase; NET, neutrophil extracellular trap; PAI-1, plasminogen activator inhibitor type 1; PT, prothrombin time; VWF, von Willebrand factor.

^aMissing data of one (non-ICU) patient for FVII and FVIII analyses (n = 22).

(Table 3). Because samples were not taken at specific time points relative to the last LMWH injection, and because there was a substantial difference in dosing and timing of LMWH administration between ICU and ward, this likely explains the difference in anti-Xa and thrombin generating capacity between ICU and ward patients.

Plasma CLT was higher in COVID-19 patients compared to healthy controls, but similar between patients on ICU and ward. Five patients had substantially elevated CLT (>100 minutes). Two of these had underlying liver disease and may have been hypofibrinolytic related to decompensating liver disease as we have described previously²⁰; the other three were all admitted to the

TABLE 3 Global hemostatic tests

	Controls (n = 20)	COVID-19 Patients (n = 23)	P Value	ICU (n = 12)	Non-ICU (n = 11)	P Value
ROTEM ^a	Reference ranges					
CT Ex (s)	50-80	70.0 [65.5-72.8]		70.5 [66.3-75.0]	69.5 [64.0-71.0]	.352
MCF Ex (mm)	55-72	68.0 [64.5-74.3]		71.0 [67.0-75.8]	66.5 [61.8-69.5]	.154
LY60 Ex (%)	94-100	99.5 [96.0-100]		100 [100-99.3]	96.0 [94.5-97.8]	<.001
CT Int (s)	161-204	180 [164-204]		193 [179-228]	170 [157-178]	.013
MCF Int (mm)	51-69	64.5 [60.8-71.3]		68.0 [63.3-71.8]	62.0 [57.0-68.5]	.261
MCF Fibtem (mm)	6-21	21.5 [13.8-26.0]		20.5 [13.3-23.0]	24.5 [17.5-29.0]	.144
TGA						
ETP (nmol/L IIa × min)	385 [243-515]	472 [153-807]	.328	185 [7.75-459]	789 [663-841]	.002
Peak (nmol/L IIa)	77.5 [47.3-126]	100 [25.0-176]	.348	40.0 [1.89-95.8]	168 [145-186]	.008
Lag time (min)	2.17 [1.67-2.33]	2.33 [1.67-3.00]	.236	2.33 [1.59-3.15]	2.33 [1.67-3.00]	.682
Velocity index (nmol/L IIa/ min)	31.0 [15.8-62.8]	54.0 [19.0-82.0]	.265	26.0 [1.50-62.8]	74.0 [54.0-88.0]	.022
Anti-Xa (U/mL)		0.13 [0.03-0.61]		0.44 [0.18-0.65]	0.03 [0.00-0.12]	.008
CLT (min)	68.1 [59.8-71.7]	80.8 [69.5-94.3]	.007	83.8 [70.6-99.4]	74.7 [61.2-89.9]	.449

Note: The results are presented as median [interquartile range]. Comparisons between the two groups were made using the Mann-Whitney *U* test for nonparametric data.

Abbreviations: anti-Xa, anti-activated factor X; CLT, clot lysis time; CT, clot time; ETP, endogenous thrombin potential; Ex, extrinsic TEM; ICU, intensive care unit; In, intrinsic TEM; LY60% of maximum MCF at 60 minutes; MCF, maximal clot firmness; ROTEM, rotational thromboelastometry; TGA, thrombin generation assay.

^aMissing data of one (non-ICU) patient for ROTEM analyses (n = 22).

TABLE 4 Markers of in vivo activation of coagulation, fibrinolysis, and platelets

	Controls (n = 20)	COVID-19 Patients (n = 23)	P Value	ICU (n = 12)	Non-ICU (n = 11)	P Value
D-dimer ^a (ng/mL)	208 [157-309]	1110 [573-5305]	<.0001	2535 [860-7848]	565 [425-2188]	.025
TAT (µg/mL)	1.55 [1.40-2.20]	7.30 [4.50-12.2]	<.0001	7.15 [4.45-8.78]	11.8 [4.50-24.1]	.355
F1 + 2 (pmol/L)	206 [158-269]	191 [145-314]	.966	218 [140-449]	186 [145-314]	.964
VIIa ^a (mU/mL)	52.0 [41.8-63.6]	27.2 [21.7-41.7]	.002	32.2 [24.5-45.2]	25.5 [10.2-30.1]	.069
PAP (ng/mL)	193 [170-240]	984 [648-2377]	<.0001	862 [484-2324]	1017 [730-2590]	.309
sCD40L (ng/mL)	52.0 [16.5-129]	83.0 [33.0-177]	.465	52.0 [20.0-148]	130 [63.0-183]	.217

Note: The results are presented as median [interquartile range]. Comparisons between the two groups were made using the Mann-Whitney *U* test for nonparametric data.

Abbreviations: F1 + 2, prothrombin fragment F1 + 2; ICU, intensive care unit; PAP, plasmin-antiplasmin; sCD40L, soluble CD40 Ligand; TAT, thrombin-antithrombin; VII(a), (activated) blood coagulation factor VII.

^aMissing data of one (non-ICU) patient for D-dimer and VIIa.

ICU, and hypofibrinolysis is a common feature of patients that are critically ill. Viscoelastic tests have shown evidence of fibrinolytic shutdown in one-quarter of COVID-19 patients and fibrinolytic shutdown was associated with thrombosis.²¹ However, the definition of hypofibrinolysis using viscoelastic tests is not straightforward because “no lysis” is in fact part of the reference range.²² We found “no lysis” (defined as CLT > 180 minutes) in only three patients (13%), whereas our plasma-based test detects “no lysis” in a much larger proportion of other patient populations (notably postsurgery²³ and patients with acute liver failure

[73.5%]²⁴). This suggests that a true fibrinolytic shutdown is rare in COVID-19, which is also evidenced by highly elevated D-dimer and plasmin-antiplasmin complexes (see the following section). Importantly, LMWH decreases CLT across physiologically relevant concentrations,²⁵ which may be why plasma clot lysis was only mildly impaired in our patients.

Thus, COVID-19 patients have somewhat elevated clot formation, likely related to hyperfibrinogenemia, normal thrombin generating capacity despite the presence of LMWH, and hypofibrinolysis despite the presence of LMWH.

3.3 | Ongoing in vivo activation of coagulation and fibrinolysis despite low therapeutic anticoagulation in COVID-19 patients

In vivo markers of activation of coagulation are shown in Table 4. TAT and PAP complex levels are strongly elevated in patients with COVID-19, indicating ongoing thrombin and plasmin generation in COVID-19 patients despite anticoagulation with LMWH. Interestingly, TAT and PAP levels were not different between patients admitted to the ICU or to the general ward, whereas D-dimer levels were substantially higher in ICU compared with ward patients. This may indicate that ICU patients have a higher clot burden, which may be primarily intrapulmonary clots,^{26,27} despite similar procoagulant activity. This might be explained by decreased (local) anticoagulant capacity in ICU patients, perhaps related to increased endothelial injury that decreases availability of thrombomodulin and endogenous heparinoids. Surprisingly, F1 + 2 levels were not increased in COVID-19 patients compared with controls, and we have no explanation for the discrepancy between TAT and F1 + 2 levels. D-dimer and TAT levels were not correlated to anti-Xa levels, but F1 + 2 levels were inversely correlated with anti-Xa levels ($r^2 = .22$, $P = .03$). The VIIa levels were lower in patients, which may point to consumption of VIIa similar to what we have previously observed in patients during the acute phase of deep vein thrombosis.²⁸ Indeed, VIIa levels strongly positively correlated with zymogen VII levels ($r^2 = .59$, $P = <.0001$). Soluble CD40 ligand levels were similar between patients and controls, suggesting COVID-19 patients are not characterized by excessive platelet activation.

Taken together, our data confirm a hypercoagulable status of enhanced thrombin generating capacity, enhanced ex vivo clot formation likely related to hyperfibrinogenemia, and a decreased ex vivo fibrinolytic capacity in patients with COVID-19. Interestingly, despite normal to intensified anticoagulant treatment, in vivo activation of coagulation and fibrinolysis was evident and independent of anti-Xa levels, whereas in vitro activation of coagulation proportionally decreased as a function of anti-Xa levels. Our observations that the hypercoagulable profile is more pronounced in the sicker patients are in line with the hypothesis that activation of coagulation, particularly in the pulmonary circulation, is a key feature of COVID-19 and may contribute to progression of disease.²⁶ These data suggest that low therapeutic anticoagulant regimens are often insufficient to downregulate coagulation activation in COVID-19 patients, and call for assessment of alternative or intensified antithrombotic strategies. However, careful individual patient assessment (especially in the critically ill) is warranted, given the increased bleeding risk that is associated with COVID-19.

CONFLICT OF INTEREST

The authors declare no competing interests.

AUTHOR CONTRIBUTIONS

Annabel Blasi: conception and design, patient inclusion, data acquisition, interpretation, revision of the manuscript; Fien A. von

Meijenfildt: interpretation, analysis, drafting of manuscript; Jelle Adelmeijer: laboratory analyses, interpretation, revision of the manuscript; Andrea Calvo: patient inclusion, interpretation, revision of the manuscript; Cristina Ibañez: patient inclusion, interpretation, revision of the manuscript; Juan Perdomo: patient inclusion, interpretation, revision of the manuscript; Juan C. Reverter: interpretation, revision of the manuscript; Ton Lisman: conception and design, analysis, supervision, interpretation, drafting of manuscript.

ORCID

Ton Lisman  <https://orcid.org/0000-0002-3503-7140>

REFERENCES

1. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020;191:145-147.
2. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost*. 2020;18(8):1995-2002.
3. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. *Transl Res*. 2020;220:1-13.
4. Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. *Crit Care Resusc*. 2020;22(2):95-97.
5. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. *N Engl J Med*. 2020;383(2):120-128.
6. Buja LM, Wolf DA, Zhao B, et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. *Cardiovasc Pathol*. 2020;48:107233.
7. Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. *Ann Intern Med*. 2020;M20-2003.
8. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost*. 2020;18(5):1094-1099.
9. Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID19 coagulopathy in Caucasian patients. *Br J Haematol*. 2020;189(6):1044-1049.
10. Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. *JCI Insight*. 2020;5(11):e138999.
11. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18(4):844-847.
12. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. *J Thromb Haemost*. 2020;18(7):1747-1751.
13. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. *J Thromb Haemost*. 2020;18(7):1738-1742.
14. Al-Samkari H, Karp Leaf RS, Dziki WH, et al. COVID and Coagulation: bleeding and thrombotic manifestations of SARS-CoV2 infection. *Blood*. 2020;136(4):489-500.
15. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive Care Med*. 2020;46(6):1089-1098.

16. von Meijenfeldt FA, Burlage LC, Bos S, Adelmeijer J, Porte RJ, Lisman T. Elevated plasma levels of cell-free DNA during liver transplantation are associated with activation of coagulation. *Liver Transpl*. 2018;24(12):1716-1725.
17. Kessenbrock K, Krumbholz M, Schonermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. *Nat Med*. 2009;15(6):623-625.
18. Bos S, van den Boom B, Kamphuisen PW, et al. Haemostatic profiles are similar across all aetiologies of cirrhosis. *Thromb Haemost*. 2019;119(2):246-253.
19. Meltzer ME, Lisman T, Doggen CJ, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. *PLoS Med*. 2008;5(5):e97.
20. Blasi A, Patel VC, Adelmeijer J, et al. Mixed fibrinolytic phenotypes in decompensated cirrhosis and acute-on-chronic liver failure with hypofibrinolysis in those with complications and poor survival. *Hepatology*. 2020;71(4):1381-1390.
21. Wright FL, Vogler TO, Moore EE, et al. Fibrinolysis shutdown correlates to thromboembolic events in severe COVID-19 infection. *J Am Coll Surg*. 2020;231(2):193-203.
22. Lisman T. Decreased fibrinolytic capacity in cirrhosis and liver transplantation outcomes. *Liver Transpl*. 2019;25(3):359-361.
23. Kleiss SF, Adelmeijer J, Meijers JCM, Porte RJ, Lisman T. A sustained decrease in plasma fibrinolytic potential following partial liver resection or pancreas resection. *Thromb Res*. 2016;140:36-40.
24. Lisman T, Bakhtiari K, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. *J Thromb Haemost*. 2012;10(7):1312-1319.
25. Lisman T, Adelmeijer J, Nieuwenhuis HK, de Groot PG. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. *Blood Coagul Fibrinolysis*. 2003;14(6):557-562.
26. Thachil J, Srivastava A. SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis or pulmonary embolism? *Semin Thromb Hemost*. 2020; in press. <https://doi.org/10.1055/s-0040-1712155>
27. Hunt BJ, Levi M. Re The source of elevated plasma D-dimer levels in COVID-19 infection. *Br J Haematol*. 2020;190(3):e133-e134.
28. Schut AM, Meijers JC, Lisman-van Leeuwen Y, et al. Decreased plasma levels of activated factor VII in patients with deep vein thrombosis. *J Thromb Haemost*. 2015;13(7):1320-1324.

How to cite this article: Blasi A, von Meijenfeldt FA, Adelmeijer J, et al. In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. *J Thromb Haemost*. 2020;00:1-8. <https://doi.org/10.1111/jth.15043>